Terms: = Thyroid cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2
48 results:
1. Targeting nrf2 to treat thyroid cancer.
Gong Z; Xue L; Li H; Fan S; van Hasselt CA; Li D; Zeng X; Tong MCF; Chen GG
Biomed Pharmacother; 2024 Apr; 173():116324. PubMed ID: 38422655
[TBL] [Abstract] [Full Text] [Related]
2. Peiminine triggers ferroptosis to inhibit breast cancer growth through triggering nrf2 signaling.
Yi N; Wang L; Jiang Z; Xu G; Li L; Zhang Y; Tan Y
Tissue Cell; 2024 Apr; 87():102323. PubMed ID: 38412577
[TBL] [Abstract] [Full Text] [Related]
3. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting nrf2.
Gong Z; Xue L; Vlantis AC; van Hasselt CA; Chan JYK; Fang J; Wang R; Yang Y; Li D; Zeng X; Tong MCF; Chen GG
J Endocrinol Invest; 2024 May; 47(5):1271-1280. PubMed ID: 38062319
[TBL] [Abstract] [Full Text] [Related]
4. Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for cancer Treatment - Pharmacology and Mechanisms.
Xing Z; Su A; Mi L; Zhang Y; He T; Qiu Y; Wei T; Li Z; Zhu J; Wu W
Drug Des Devel Ther; 2023; 17():2909-2929. PubMed ID: 37753228
[TBL] [Abstract] [Full Text] [Related]
5. USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing nrf2.
Cui J; Guo Y; Yin T; Gou S; Xiong J; Liang X; Lu C; Peng T
Biomed Pharmacother; 2023 Oct; 166():115359. PubMed ID: 37639742
[TBL] [Abstract] [Full Text] [Related]
6. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
7. Antioxidant Defense Capacity Is Reduced in thyroid Stem/Precursor Cells Compared to Differentiated Thyrocytes.
Gianì F; Allia F; Trovato MA; Masto R; Pellegriti G; Vigneri R
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511265
[TBL] [Abstract] [Full Text] [Related]
8. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis.
Wang Z; Li R; Hou N; Zhang J; Wang T; Fan P; Ji C; Zhang B; Liu L; Wang Y; Kong J; Yao Q; Duan J; Zhao G; Ling R; Zhang J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37380368
[TBL] [Abstract] [Full Text] [Related]
9. nrf2 as a novel diagnostic biomarker for papillary thyroid carcinoma.
Wang Z; Li J; Liu Z; Yue L
Eur J Histochem; 2023 Mar; 67(2):. PubMed ID: 36951264
[TBL] [Abstract] [Full Text] [Related]
10. Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica.
He T; Zhou F; Su A; Zhang Y; Xing Z; Mi L; Li Z; Wu W
Biomed Pharmacother; 2023 Feb; 158():114134. PubMed ID: 36525821
[TBL] [Abstract] [Full Text] [Related]
11. ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-nrf2/HO-1 axis.
Li W; Huang G; Wei J; Cao H; Jiang G
Mol Cell Biochem; 2023 Apr; 478(4):729-741. PubMed ID: 36070054
[TBL] [Abstract] [Full Text] [Related]
12. The Cross-Talk between Polyphenols and the Target Enzymes Related to Oxidative Stress-Induced thyroid cancer.
Heydarzadeh S; Kia SK; Zarkesh M; Pakizehkar S; Hosseinzadeh S; Hedayati M
Oxid Med Cell Longev; 2022; 2022():2724324. PubMed ID: 35571253
[TBL] [Abstract] [Full Text] [Related]
13. Naringenin Regulates FKBP4/NR3C1/nrf2 Axis in Autophagy and Proliferation of Breast cancer and Differentiation and Maturation of Dendritic Cell.
Xiong H; Chen Z; Lin B; Xie B; Liu X; Chen C; Li Z; Jia Y; Wu Z; Yang M; Jia Y; Wang L; Zhou J; Meng X
Front Immunol; 2021; 12():745111. PubMed ID: 35087512
[TBL] [Abstract] [Full Text] [Related]
14. The Knockdown of nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic thyroid cancer.
Gong Z; Xue L; Wei M; Liu Z; Vlantis AC; van Hasselt CA; Chan JYK; Li D; Zeng X; Tong MCF; Chen GG
Oxid Med Cell Longev; 2021; 2021():3900330. PubMed ID: 34527171
[TBL] [Abstract] [Full Text] [Related]
15. Novel Anaplastic thyroid cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
[TBL] [Abstract] [Full Text] [Related]
16. Pan-cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many cancers.
Qureshi MA; Khan S; Tauheed MS; Syed SA; Ujjan ID; Lail A; Sharafat S
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3199-3209. PubMed ID: 33247676
[TBL] [Abstract] [Full Text] [Related]
17. The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the nrf2/HO1 pathway.
He L; Zhang T; Sun W; Qin Y; Wang Z; Dong W; Zhang H
Med Oncol; 2020 Oct; 37(11):97. PubMed ID: 33001278
[TBL] [Abstract] [Full Text] [Related]
18. FosB recruits KAT5 to potentiate the growth and metastasis of papillary thyroid cancer in a DPP4-dependent manner.
Du J; Fu L; Ji F; Wang C; Liu S; Qiu X
Life Sci; 2020 Oct; 259():118374. PubMed ID: 32891613
[TBL] [Abstract] [Full Text] [Related]
19.
Stuchi LP; Castanhole-Nunes MMU; Maniezzo-Stuchi N; Biselli-Chicote PM; Henrique T; Padovani Neto JA; de-Santi Neto D; Girol AP; Pavarino EC; Goloni-Bertollo EM
Genes (Basel); 2020 Aug; 11(9):. PubMed ID: 32824922
[TBL] [Abstract] [Full Text] [Related]
20. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract] [Full Text] [Related]
[Next]
